Dapsone
Chronic Myeloproliferative Disorders
Vanderbilt UniversitySmall moleculeDormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 81/ 100
Competitive context
80 Active assets in the Chronic Myeloproliferative Disorders cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Evomela Center for International Blood and Marrow Transplant Research | Phase 2/3 | BBB |
Fludarabine Sawa Ito, MD | Phase 4 | BB |
Anti-Thymoglobulin, Rabbit Fred Hutchinson Cancer Center | Phase 2/3 | BB |
Busulphan Sawa Ito, MD | Phase 4 | BB |
Fludarabine Sawa Ito, MD | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Dapsone is also rated in:
Cetuximab-induced Papulopustular (Acneiform) Rash Who HaveDormant
BB
Indicative ·
64 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →